INTRODUCTION
Radical prostatectomy (RP) is one of the first-line treatment options for patients with organ-confined prostate cancer. However, 40% of men treated with RP will experience biochemical recurrence (BCR) within 5 years. Salvage radiotherapy (SRT) is currently the recommended option for patients with BCR. Nevertheless, a significant number of patients undergoing SRT for BCR following RP may again experience BCR after SRT. Several studies have found that various factors such as Gleason score (GS), pathological tumor (pT) stage, SRT combined with androgen deprivation therapy (ADT), radiation dose, perineural invasion, preoperative prostate-specific antigen (PSA), surgical margin, and seminal vesicle involvement (SVI) are associated with BCR after SRT. However, there have been conflicting results and the predictive factors for BCR remain to be clearly established. An increasing number of new publications on this controversial subject have emerged in recent years.

We conducted a systematic review and meta-analysis to evaluate the factors influencing BCR after SRT to build predictive models to help clinicians identify the best candidates who will benefit from SRT.

MATERIALS AND METHODS
Identification of eligible studies
We searched the following electronic databases: PubMed, Embase, and Web of Science from inception to June 15, 2015. The search was performed using the following terms in “All fields”: “salvage radiation therapy,” “salvage IMRT,” “S-IMRT,” “salvage radiotherapy,” “SRT,” “radical prostatectomy,” “RP,” “biochemical recurrence,” “BCR,” “biochemical relapse.” Eleven studies, with a total of 1383 patients, were included in our meta-analysis. Of all the variables, only Gleason score (GS) ≥7 (odds ratio [OR]: 3.82; 95% confidence interval [CI]: 2.60–5.64) and pathological tumor (pT) stage ≥3a (OR: 1.82; 95% CI: 1.36–2.42) were positively correlated with BCR. However, SRT combined with androgen deprivation therapy (ADT) (OR: 0.63; 95% CI: 0.44–0.90) and radiation therapy (RT) dose ≥64 Gy (OR: 0.35; 95% CI: 0.19–0.64) were negatively correlated with BCR. Perineural invasion (OR: 2.64; 95% CI: 1.11–6.26), preoperative prostate-specific antigen (PSA) ≥10 ng ml⁻¹ (OR: 1.36; 95% CI: 0.94–1.96), positive surgical margin (OR: 0.92; 95% CI: 0.7–1.19), and seminal vesicle involvement (SVI) (OR: 1.09; 95% CI: 0.83–1.43) had no effect on BCR. Our meta-analysis indicated that pT stage, GS, RT dose, and SRT combined with ADT may influence BCR, while preoperative PSA, surgical margin, perineural invasion, and SVI have only a weak effect on BCR.

Asian Journal of Andrology (2017) 19, 493–499; doi: 10.4103/1008-682X.179531; published online: 31 May 2016

Keywords: biochemical recurrence; prostate cancer; radical prostatectomy; risk factors; salvage radiotherapy

ORIGINAL ARTICLE
Factors influencing biochemical recurrence in patients who have received salvage radiotherapy after radical prostatectomy: a systematic review and meta-analysis

Zhong-Wei Jia¹,², Kun Chang¹,², Bo Dai¹,², Yun-Yi Kong¹,², Yue Wang¹,², Yuan-Yuan Qu¹,², Yi-Ping Zhu¹,², Ding-Wei Ye¹,²

Several studies have evaluated the risk factors influencing biochemical recurrence (BCR) of prostate cancer in patients receiving salvage radiotherapy (SRT) for BCR after radical prostatectomy (RP), but the results remain conflicting. In this study, we performed a meta-analysis to resolve this conflict. We searched the following databases: PubMed, Embase, and Web of Science using the following terms in “All fields”: “salvage radiation therapy,” “salvage IMRT,” “S-IMRT,” “salvage radiotherapy,” “SRT,” “radical prostatectomy,” “RP,” “biochemical recurrence,” “BCR,” “biochemical relapse.” Eleven studies, with a total of 1383 patients, were included in our meta-analysis. Of all the variables, only Gleason score (GS) ≥7 (odds ratio [OR]: 3.82; 95% confidence interval [CI]: 2.60–5.64) and pathological tumor (pT) stage ≥3a (OR: 1.82; 95% CI: 1.36–2.42) were positively correlated with BCR. However, SRT combined with androgen deprivation therapy (ADT) (OR: 0.63; 95% CI: 0.44–0.90) and radiation therapy (RT) dose ≥64 Gy (OR: 0.35; 95% CI: 0.19–0.64) were negatively correlated with BCR. Perineural invasion (OR: 2.64; 95% CI: 1.11–6.26), preoperative prostate-specific antigen (PSA) ≥10 ng ml⁻¹ (OR: 1.36; 95% CI: 0.94–1.96), positive surgical margin (OR: 0.92; 95% CI: 0.7–1.19), and seminal vesicle involvement (SVI) (OR: 1.09; 95% CI: 0.83–1.43) had no effect on BCR. Our meta-analysis indicated that pT stage, GS, RT dose, and SRT combined with ADT may influence BCR, while preoperative PSA, surgical margin, perineural invasion, and SVI have only a weak effect on BCR.

Keywords: biochemical recurrence; prostate cancer; radical prostatectomy; risk factors; salvage radiotherapy

1Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; 2Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China; 3Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.

*These authors contributed equally to this work.

Correspondence: Dr. B Dai (bodai1978@126.com)
Received: 26 June 2015; Revised: 25 September 2015; Accepted: 23 February 2016
who had BCR after 5 years of follow-up. The exclusion criteria were as follows: (1) interventions that did not include SRT and (2) studies that contained data that could not be extracted and any attempts to obtain the information from the authors had failed.

Data extraction
Data were extracted independently by two authors (ZWJ and KC) using a standardized form and any disagreement was resolved by consensus between the two authors or consultation with a third reviewer. The data extracted from each paper included first authorship, country of origin, year of publication, age of patients, follow-up duration, BCR rate after 5 years follow-up, study size, and patient demographics, including GS, pT stage, SRT combined with ADT, radiation dose, perineural invasion, preoperative PSA, surgical margin, and SVI.

Statistical methods
Review Manager version 5.2 (Cochrane Collaborative, Oxford, UK) was used to integrate all the individual outcomes. Statistical heterogeneity among studies was evaluated based on the χ² test and I² test. Significant heterogeneity was considered when P < 0.10 and I² = >50%. Publication bias was evaluated by the funnel plot and Begg’s rank regression test using STATA version 12.0 (Stata Corporation, College Station, TX, USA). Publication bias was significant at P < 0.1.

RESULTS
Study inclusion
Figure 1 shows the flowchart of papers retrieved and excluded. We identified 1250 papers from the database search and retrieved the full text for 204 based on abstract reviews. Of these 204 papers, 196 were finally excluded because they did not meet the inclusion criteria. In addition, four papers were identified from the reference lists. Finally, a total of 11 papers were eligible for review. Any disagreements at this stage were resolved by consensus.

Study characteristics
The characteristics of the eligible studies are summarized in Table 1. The 11 studies in this meta-analysis were published from 2003 to 2014, and the study size ranged from 35 to 472 patients. Of the 11 studies, four were conducted in Europe, three in Asia, three in North America, and 1 in Latin America. The patients’ age ranged from 39 to 81 years and the follow-up duration was 3–157.1 months. In addition, the BCR rate after SRT ranged from 23.3% to 79.7% at 5 years.

Main outcomes
The clinical or pathological risk factors influencing BCR of prostate cancer in patients who received SRT for BCR following RP are shown in Figures 2–9. SRT was defined as local radiotherapy to the prostatic bed alone following BCR after RP. BCR after RP was defined as PSA level ≥0.2 ng ml⁻¹ with two consecutive increases from a baseline of <0.2 ng ml⁻¹. BCR after SRT was defined as a PSA level that had increased to ≥0.2 ng ml⁻¹ from the post-RT nadir confirmed by one more consecutive result.

Preoperative PSA
Five studies including 561 patients showed a weak association between preoperative PSA ≥10 ng ml⁻¹ group and preoperative PSA <10 ng ml⁻¹ group (odds ratio [OR]: 1.36; 95% confidence interval [CI]: 0.94–1.96). The fixed-effects model was reported here because there was no evidence of heterogeneity (I² = 29%) (Figure 2).

GS
Four studies including 841 patients showed a weak association between GS ≥7 and GS <7. The overall effect of this meta-analysis was against the patients with GS ≥7 (OR: 3.82; 95% CI: 2.60–5.64). The random-effects model was reported here because there was evidence of significant heterogeneity (I² = 59%) (Figure 3).

pT stage
Seven studies including 1024 patients reported the relationship between pT stage and BCR. When these results were pooled, pT ≥3a was a significant factor predicting BCR after SRT (OR: 1.87; 95% CI: 1.08–3.23). The random-effects model was reported here because there was evidence of significant heterogeneity (I² = 61%) (Figure 4).

Surgical margin
Positive surgical margins indicate the presence of remnant tumors in the surgical bed, but their impact on cancer progression remains a topic of debate. Four studies evaluated the surgical margins including 264 patients that evaluated radiation dose. In this meta-analysis, each study size ranged from 35 to 472 patients. Of the 11 studies, four were conducted in Europe, three in Asia, three in North America, and 1 in Latin America. The patients’ age ranged from 39 to 81 years and the follow-up duration was 3–157.1 months. In addition, the BCR rate after SRT ranged from 23.3% to 79.7% at 5 years.

SRT combined with ADT
SRT combined with ADT may be a treatment option for patients with a higher probability of relapse after SRT. However, the effect remains a topic of debate. Five studies including 292 patients who were given ADT with SRT and 278 who were not given concomitant ADT as a control group. The overall effect of this meta-analysis favored ADT with salvage RT (OR: 0.63; 95% CI: 0.44–0.90). The fixed-effects model was reported here because there was no evidence of heterogeneity (I² = 4%) (Figure 6).

Radiation dose
Until now, no prospective data have been published regarding the most efficacious dose of SRT. In this meta-analysis, we evaluated three studies including 264 patients that evaluated radiation dose. Pooling of data from these studies showed a significant effect of radiation dose ≥64 Gy versus the controls (OR: 0.35; 95% CI: 0.19–0.64). The fixed-effects model was used here because there was no evidence of heterogeneity (I² = 0%) (Figure 7).
Perineural invasion

Two studies\(^{10,20}\) evaluated perineural invasion, including 106 patients in the positive group and 39 patients in the negative group. The overall effect of this meta-analysis showed no significant association between the two groups (OR: 2.64; 95% CI: 1.11–6.26). The random-effects model was used here because there was no evidence of heterogeneity ($I^2 = 70\%$) (Figure 8).

SVI

Five studies\(^{10,14,15,17,20}\) including a total of 408 patients reported the relationship between SVI and BCR. Pooling of data from these studies showed no significant difference between the positive and negative groups (OR: 0.91; 95% CI: 0.54–1.53). The fixed-effects model was used here because there was no evidence of heterogeneity ($I^2 = 0\%$) (Figure 9).

Publication bias and sensitivity analysis

We performed a funnel plot and Egger’s test to assess publication bias. The funnel plots were symmetrical among the studies included (Figure 10). Consistent with this, we found no evidence of publication bias by Egger’s test ($P = 0.453$). We performed leave-one-out sensitivity analysis and the results indicated that a single study could not qualitatively change the pooled ORs.
DISCUSSION

Based on the well-known association between SRT and cancer control outcomes, it is recommended that SRT should be administered to patients with BCR after RP. However, some men still experience BCR, even when SRT is administered early after BCR. Many factors may affect BCR; however, there are conflicting results and the predictive factors...
for BCR remain to be clearly established. Thus, evaluating the clinical significance of different clinic-pathological parameters in BCR after SRT and identifying patients who may benefit from post-RP radiation are critical for improving outcomes in the salvage setting. For this purpose, BCR-related variables involved in the outcome of patients receiving post-RP RT are of major significance.

This study was the first systematic review and meta-analysis of the risk factors for BCR among patients who have received SRT for BCR following RP. We included 11 studies from 2003 to 2014 with a total of 1383 patients. Our analysis shows that GS, pT, SRT combined with ADT, and radiation dose are associated with the risk of BCR.

Although the predictive value of GS has been reported in several studies, the results remain controversial. One study conducted by Monti et al.\textsuperscript{13} did not find any association between GS and BCR. However, Peyromaure et al.\textsuperscript{16} and Stephenson et al.\textsuperscript{21} found that GS ≥8 was associated with a high risk of BCR. Consistent with our findings, Song et al.\textsuperscript{22} reported that a GS ≥7 was an accurate predictor of BCR after SRT. In general, we found that GS ≥7 was a risk factor for BCR. Several recent studies have reported that pT stage was a risk factor predicting BCR after SRT. However, the specific stage was not consistent. In our study, pT ≥3a was a significant factor predicting BCR after SRT. For patients with pT ≥3a disease, SRT may not be effective, and postoperative RT may improve biochemical relapse-free survival (bRFS). One study conducted by Jereczek-Fossa et al.\textsuperscript{23} reported that bRFS in postoperative RT patients was significantly longer than that of patients who had undergone SRT (4-year biochemical control rates: 81.7% vs 60.5%, respectively).

SRT combined with ADT may be an effective treatment option for preventing BCR after SRT. However, the efficacy of this strategy for reducing cancer recurrence remains a topic of debate. Our results
indicated that BCR was significantly reduced in patients who received SRT combined with ADT. In contrast, Trock found that SRT combined with ADT did not decrease BCR after SRT, while several other studies reported that ADT administered concurrently with SRT was predictive of favorable patient outcomes. Notably, Stephenson et al. found that ADT administered before and/or during SRT may improve the efficacy of SRT, consistent with our results. SRT was administered at a total dose of 60–70 Gy (median 66 Gy) in the current study, but the optimal dose of SRT remains controversial, and no prospective data are currently available. The Therapeutic Radiology and Oncology (ASTRO) Consensus Panel suggested the highest dose of radiation therapy that can be given without morbidity is justifiable. In this study, we found that the effect of SRT might be improved with a dose of ≥64 Gy. However, the possible side effects should also be taken into consideration when choosing the appropriate dose of SRT. Several studies reported that a dose <64 Gy is rarely associated with severe side effects, while other studies reported that a dose >68 Gy was associated with an increase in late grade 3 urinary toxicity.

In general, patients have a bad prognosis if their surgical margins are positive. However, several studies showed that patients are more likely to have better prognosis if their surgical margins are positive. Some studies have reported to the contrary. Brighenti et al. reported that a positive surgical margin may be a risk factor of BCR after SRT. Meanwhile, a study conducted by Umezawa et al. showed that the status of the surgical margin did not affect BCR after SRT. This was consistent with our results, which showed that there is no significant association between surgical margins and BCR. In several studies, patients with preoperative PSA >20 ng ml⁻¹ were excluded from SRT, and the ideal patient has preoperative PSA <10 ng ml⁻¹. However, our study did not find any obvious association between preoperative PSA and BCR after SRT. Patients with the involvement of SVI are usually excluded from SRT as well but, in our study, the correlation was not obvious. Meantime, we find no matter what the status of perineural, the results may not have statistically significant. It is not clear what caused this phenomenon. Although we found a significant difference, only eight, five, five, and two articles were included to evaluate surgical margin, preoperative PSA, SVI, and perineural invasion, respectively. We look forward to more studies, with large sample sizes, to confirm our findings.

PSA doubling time (PSADT) has recently been used as a parameter to identify appropriate patients for SRT after BCR in clinical practice. Trock reported that patients with PSADT <6 months may experience significantly improved prostate cancer-specific survival. However, Umezawa et al. and Stephenson et al. found different results; Umezawa et al. showed that patients with PSADT <7 months had poorer survival and a lower 4-year bRFS rate than patients with PSADT ≥7 months, while Stephenson et al. found that patients with PSADT ≤10 months had poorer survival, irrespective of GS state and surgical margin. However, there is currently no definitive cut-off value for SRT to help identify appropriate patients for SRT. In addition, pre-SRT PSA level and PSA nadir after RP might predict the results of SRT after BCR. The significance of these parameters should be verified in large prospective studies.

Imaging is a valuable targeted tool for predicting patients' prognosis. Positron emission tomography/computed tomography (PET/CT) using ¹¹C-labeled choline may help to identify patients likely to benefit from SRT, given that ¹¹C-choline PET/CT can detect the site of tumor recurrence earlier than other imaging methods. Castellucci et al. found that positive scan results were positively correlated with PSA level, ongoing ADT, and PSADT, while Souvatzoglou et al. also found that patients with positive ¹¹C-choline PET/CT results had significantly higher PSA levels. In addition, Rodado-Marina et al. revealed that PSA >3 ng ml⁻¹, no early RP, and GS ≥8 were independent risk factors for positive PET/CT in a study of 233 patients. Although the results of the above studies are not identical, they suggest that choline-PET/CT may be a useful predictive imaging tool.

Despite the above positive findings, we remain cautious in our conclusions, as our study was not devoid of some limitations. First, we considered only a single risk factor. However, BCR may be affected by one or more factors. We tried to extract adjusted data from the studies included; however, most of the papers did not report adjusted hazard ratios in multivariate analysis. Our study may only provide some references and we hope that more papers with adjusted data will be published in the future to provide further research. Second, the initial RP was performed by different doctors, even though each operation was carried out according to the standard method. Therefore, the surgical quality may differ and the results may display heterogeneity. Third, we used BCR as the primary endpoint, but did not take comorbidity into account. However, some patients who experience BCR will die from diseases other than prostate cancer. The absence of analysis of accurate PSA data after BCR may be another limitation of our study because we could not distinguish the importance of each risk factor. In addition, our meta-analysis only included 11 articles related to the risk factors and the results need verification.

**CONCLUSIONS**

Our meta-analysis suggests that GS ≥7, pT ≥3a, and SRT not combined with ADT and radiation dose <64 Gy are risk factors for BCR among patients who have received SRT for BCR following RP. However, preoperative PSA, surgical margin, perineural invasion, and SVI have no effect on BCR. Our predictive models might help clinicians to identify the best candidates who will benefit from SRT.

**AUTHOR CONTRIBUTIONS**

ZWJ and KC drafted the manuscript. BD and DWY supervised and revised the manuscript. YW and YYQ searched and selected the studies. YYK and HLZ collected the clinical data, and YZ and GHS analyzed the data. All authors reviewed and approved the manuscript.
COMPETING INTERESTS
All authors declare no competing interests.

ACKNOWLEDGMENTS
This study was supported by a grant from the International Cooperation and Exchange of Science and Technology Commission of Shanghai Municipality (No. 12410709300), a grant from the Guide Project of Science and Technology Commission of Shanghai Municipality (No. 124119a7300), and a grant from the Outstanding Young Talent Training Plan of Shanghai Municipal Commission of Health and Family Planning (No. XYQ2013102).

REFERENCES
1. Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, et al. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol 2012; 188: 2219–24.
2. Mullins JK, Feng Z, Trock BJ, Epstein JJ, Walsh PC, et al. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. J Urol 2012; 188: 2219–24.
3. Tanaka N, Fujimoto K, Hirayama A, Nakai Y, Chihara Y, et al. Calculated tumor volume is an independent predictor of biochemical recurrence in patients who underwent retropubic radical prostatectomy. Adv Urol 2012; 2012: 1–7.
4. Okajima E, Yoshikawa M, Masuda Y, Shimizu K, Tanaka N, et al. Improvement of the surgical curability of locally confined prostate cancer including non-organ-confined high-risk disease through retropubic radical prostatectomy with intentional wide resection. World J Urol 2012; 10: 249.
5. Pfister D, Boilla M, Briganti A, Carroll P, Cozzarini C, et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol 2014; 65: 1034–43.
6. Karlén JD, Koontz BF, Freedland SJ, Moul JW, Grob BM, et al. Identifying appropriate patients for early salvage radiotherapy after prostatectomy. J Urol 2013; 190: 1410–5.
7. Trock BJ. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 2760.
8. Algarra R, Tienza A, Hervia M, Zudaire J, Rosell D, et al. Influential factors in the response to salvage radiotherapy after radical prostatectomy. Actas Urol Esp 2014; 38: 662–8.
9. Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, et al. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol 2014; 66: 479–86.
10. Miyake M, Tanaka N, Asakawa I, Morizawa Y, Anai S, et al. Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study. Radiat Oncol 2014; 9: 208.
11. Kwon O, Kim KB, Lee YI, Byun SS, Kim JS, et al. Salvage radiotherapy after radical prostatectomy: prediction of biochemical outcomes. PLoS One 2014; 9: e103574.
12. Mueller KF, Meerpohl JJ, Briel M, Antes G, von Elm E, et al. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? J Nucl Med 2014; 55: 1424–9.
13. Castellucci P, Ceci F, Graziani T, Schiavina R, Brunocilla E, et al. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? J Nucl Med 2014; 55: 1424–9.
14. Milecki P, Antczak A, Martenka P, Kwasz I. What is the possible role of PSA doubling time (PSADT) and PSA velocity (PSAV) in the decision-making process to initiate salvage radiotherapy following radical prostatectomy in patients with prostate cancer? Curr European J Urol 2011; 63: 64.
15. Castellucci P, Ceci F, Graziani T, Schiavina R, Brunocilla E, et al. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? J Nucl Med 2014; 55: 1424–9.
16. Bolla M, de la Rosette JJ, van Tinteren H, van der Kwast TH, et al. Improved local control by short-course postoperative androgen deprivation after prostatectomy for high-risk disease through retropubic radical prostatectomy with intentional wide resection. World J Urol 2012; 10: 249.
17. Pfister D, Boilla M, Briganti A, Carroll P, Cozzarini C, et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol 2014; 65: 1034–43.
18. Karlén JD, Koontz BF, Freedland SJ, Moul JW, Grob BM, et al. Identifying appropriate patients for early salvage radiotherapy after prostatectomy. J Urol 2013; 190: 1410–5.
19. Trock BJ. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 2760.
20. Algarra R, Tienza A, Hervia M, Zudaire J, Rosell D, et al. Influential factors in the response to salvage radiotherapy after radical prostatectomy. Actas Urol Esp 2014; 38: 662–8.
21. Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, et al. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol 2014; 66: 479–86.
22. Miyake M, Tanaka N, Asakawa I, Morizawa Y, Anai S, et al. Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study. Radiat Oncol 2014; 9: 208.
23. Kwon O, Kim KB, Lee YI, Byun SS, Kim JS, et al. Salvage radiotherapy after radical prostatectomy: prediction of biochemical outcomes. PLoS One 2014; 9: e103574.
24. Mueller KF, Meerpohl JJ, Briel M, Antes G, von Elm E, et al. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? J Nucl Med 2014; 55: 1424–9.
25. Castellucci P, Ceci F, Graziani T, Schiavina R, Brunocilla E, et al. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? J Nucl Med 2014; 55: 1424–9.
26. Milecki P, Antczak A, Martenka P, Kwasz I. What is the possible role of PSA doubling time (PSADT) and PSA velocity (PSAV) in the decision-making process to initiate salvage radiotherapy following radical prostatectomy in patients with prostate cancer? Curr European J Urol 2011; 63: 64.